Methotrexate · oral tablet
Misc.
Approved uses
Rheumatoid arthritis (adults) and polyarticular juvenile idiopathic arthritis (pediatric patients)
Rheumatoid arthritis: 7.5 mg orally once weekly, escalated to optimal response. pJIA: 10 mg/m2 orally once weekly, escalated to optimal response.
The once-weekly schedule is the single most dangerous thing on this card: daily dosing by mistake has killed people
Acute lymphoblastic leukemia, mycosis fungoides, relapsed or refractory non-Hodgkin lymphomas, and severe psoriasis
ALL: 20 mg/m2 orally once weekly in a combination maintenance regimen. Mycosis fungoides: 25 mg to 75 mg orally once weekly as a single agent, or 10 mg/m2 orally twice weekly in combination chemotherapy. Non-Hodgkin lymphomas: 2.5 mg orally 2 to 4 times per week (maximum 10 mg per week). Psoriasis: 10 mg to 25 mg orally once weekly; do not exceed 30 mg per week.
OFF-LABELNot in the FDA label for this product
Non-infectious uveitis, as a corticosteroid-sparing agent
25 mg orally once weekly in the trial
RCT · n=216 · best posterior
The FAST trial randomized 216 adults with non-infectious uveitis to methotrexate 25 mg weekly or mycophenolate 3 g daily. Treatment success at 6 months was 66.7% on methotrexate against 57.1% on mycophenolate, which did not reach significance overall (odds ratio 1.50, 95% CI 0.81 to 2.81, p=0.20). The useful finding is the split by anatomy: methotrexate was better for posterior uveitis and panuveitis (74.4% against 55.3%, p=0.02) while mycophenolate was better for intermediate uveitis (63.6% against 33.3%, p=0.07), and the interaction between drug and subtype was significant at p=0.004. Raised liver enzymes were the commonest laboratory problem, in 13.0% on methotrexate.
Contraindications
- Pregnancy, when methotrexate is used for a non-neoplastic disease
- History of a severe hypersensitivity reaction to methotrexate, including anaphylaxis
Methotrexate tablets USP, 2.5 mg, scored; bottles of 36 and 100
Methotrexate inhibits dihydrofolic acid reductase. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication.
Warnings & Precautions
- Embryo-fetal toxicity (boxed warning): Methotrexate can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases it is contraindicated in pregnancy; for neoplastic diseases, advise of the potential risk to a fetus. Females of reproductive potential should use effective contraception during treatment and for 6 months after the final dose, and males with female partners of reproductive potential for 3 months.
- Hypersensitivity reactions (boxed warning): Hypersensitivity reactions, including anaphylaxis, can occur. If anaphylaxis or other serious hypersensitivity reaction occurs, immediately and permanently discontinue methotrexate. It is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate.
- Serious adverse reactions (boxed warning): Serious adverse reactions, including death, have been reported. Closely monitor for adverse reactions of the bone marrow, gastrointestinal tract, liver, lungs, skin and kidneys, and withhold or discontinue as appropriate.
- Medication errors (boxed warning): Deaths occurred as a result of medication errors, most commonly in patients taking methotrexate daily when a weekly dosing regimen was prescribed. Instruct patients and caregivers to take the recommended dosage as directed.
- Myelosuppression: Methotrexate can cause severe and life-threatening pancytopenia, anemia, leukopenia, neutropenia and thrombocytopenia. Obtain blood counts at baseline, periodically during treatment and as clinically indicated. Withhold, dose reduce or discontinue as appropriate.
- Gastrointestinal toxicity: Diarrhea, vomiting, nausea and stomatitis occurred in up to 10% of patients treated for non-neoplastic diseases. Hemorrhagic enteritis and fatal intestinal perforation have been reported. Patients with peptic ulcer disease or ulcerative colitis are at greater risk of severe reactions. Withhold or discontinue for severe gastrointestinal toxicity.
- Hepatotoxicity: Severe and potentially irreversible hepatotoxicity can occur, including fibrosis, cirrhosis and fatal liver failure. Safety in hepatic disease is unknown; heavy alcohol consumption increases the risk. In psoriasis, fibrosis or cirrhosis may occur without symptoms or abnormal liver tests; the risk appears to increase with total cumulative dose and generally occurs after 1.5 g or more. Monitor liver tests at baseline, periodically and as clinically indicated; withhold or discontinue as appropriate.
- Pulmonary toxicity: Pulmonary toxicity, including acute or chronic interstitial pneumonitis and irreversible or fatal cases, can occur. Monitor for pulmonary toxicity and withhold or discontinue as appropriate.
- Dermatologic reactions: Severe, including fatal, dermatologic reactions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, skin necrosis and erythema multiforme can occur. Ultraviolet exposure may aggravate psoriasis, and radiation recall dermatitis and photodermatitis reactivation can occur. Withhold or permanently discontinue for severe reactions. Advise patients to avoid excessive sun exposure and use sun protection.
- Renal toxicity: Methotrexate can cause renal toxicity, including irreversible acute renal failure. Monitor renal function at baseline, periodically and as clinically indicated, and withhold or discontinue for severe renal toxicity. Administer glucarpidase for toxic plasma methotrexate concentrations (> 1 micromole per liter) with delayed clearance due to impaired renal function.
- Folic acid supplementation: In neoplastic diseases, products containing folic acid or its derivatives may decrease the clinical effectiveness of methotrexate, so patients should take them only when directed. In non-neoplastic diseases, folate deficiency may increase methotrexate adverse reactions, so administer folic acid or folinic acid for rheumatoid arthritis, pJIA and psoriasis.
- Serious infections: Patients are at increased risk of life-threatening or fatal bacterial, fungal or viral infections, including opportunistic infections such as Pneumocystis jiroveci pneumonia, invasive fungal infections, hepatitis B reactivation, tuberculosis, and disseminated Herpes zoster and cytomegalovirus infections. Monitor during and after treatment, and withhold or discontinue as appropriate.
- Neurotoxicity: Methotrexate can cause severe acute and chronic neurotoxicity, which can be progressive, irreversible and fatal. The risk of leukoencephalopathy is increased after prior cranial radiation. Monitor for neurotoxicity and withhold or discontinue as appropriate.
- Secondary malignancies: Secondary malignancies can occur. The risk of cutaneous malignancies is further increased when cyclosporine is given to psoriasis patients who received prior methotrexate. In some cases, lymphoproliferative disease during low-dose therapy regressed completely after withdrawal. If lymphoproliferative disease occurs, discontinue methotrexate.
- Tumor lysis syndrome: Methotrexate can induce tumor lysis syndrome in patients with rapidly growing tumors. Institute appropriate prophylactic measures in patients at risk before starting.
- Risks associated with live vaccines: Disseminated infections following administration of live vaccines have been reported. Immunization with live vaccines is not recommended during treatment. Update immunizations according to immunization guidelines before starting methotrexate.
- Infertility: Methotrexate can cause impairment of fertility, oligospermia and menstrual dysfunction. It is not known if the infertility may be reversible. Discuss the risk of infertility with females and males of reproductive potential.
- Third-space accumulation: Methotrexate accumulates in third spaces (e.g., pleural effusions or ascites), which prolongs elimination and increases the risk of adverse reactions. Evacuate significant third-space accumulations before administration.
Common Side Effects
Common adverse reactions were ulcerative stomatitis, leukopenia, nausea and abdominal distress. Other clinically relevant adverse reactions were infection, malaise, fatigue, chills, fever and dizziness. In rheumatoid arthritis trials, elevated liver tests occurred in 15% and nausea/vomiting in 10%. Serious adverse reactions include myelosuppression, hepatotoxicity, interstitial pneumonitis, renal toxicity and severe dermatologic reactions.
Pregnancy: Contraindicated in pregnant women with non-neoplastic diseases. Methotrexate can cause embryo-fetal toxicity and fetal death; advise pregnant women with neoplastic diseases of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential before starting. Females of reproductive potential should use effective contraception during treatment and for 6 months after the final dose, and males with female partners of reproductive potential for 3 months.
Lactation: Limited published literature reports methotrexate in human milk in low amounts. Because of the potential for serious adverse reactions in a breastfed child, instruct women not to breastfeed during treatment and for 1 week after the final dose.
Safety and effectiveness have been established in pediatric patients for ALL as part of the combination chemotherapy maintenance regimen and for pJIA. No new safety signals have been observed in pediatric clinical studies. Safety and effectiveness have not been established in pediatric patients for the other indications.